Identification of the Drivers of Disease Progression in Cutaneous T Cell Lymphoma

We hypothesize that CTCL, like other cancers, harbors clinically actionable genetic drivers of disease progression and propose a comprehensive genomics approach to identify these mutations. To find these mutations, we will utilize my lab’s expertise in genomics to genetically analyze a large cohort of CTCL patients (>420 cases) from Northwestern’s robust clinically annotated biobank. Specifically, our aims are to perform 1) whole genome sequencing of paired samples pre- and post disease progression and 2) targeted resequencing of a cohort of unpaired Stage I, II, III, and IV CTCLs.